Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells

Molecular Therapy Nucleic Acids

Volumn 1, Issue 1, 2012, Pages e4-

  Novobrantseva, Tatiana I ^a   Borodovsky, Anna ^a   Wong, Jamie ^a   Klebanov, Boris ^a   Zafari, Mohammad ^a   Yucius, Kristina ^a   Querbes, William ^a   Ge, Pei ^a   Ruda, Vera M ^b   Milstein, Stuart ^a   Speciner, Lauren ^a   Duncan, Rick ^a   Barros, Scott ^a   Basha, Genc ^c   Cullis, Pieter ^c   Akinc, Akin ^a   Donahoe, Jessica S ^b   Jayaprakash, K Narayanannair ^a   Jayaraman, Muthusamy ^a   Bogorad, Roman L ^d   Love, Kevin ^d,e   Whitehead, Katie ^d,e   Levins, Chris ^d,e   Manoharan, Muthiah ^a   Swirski, Filip K ^b   Weissleder, Ralph ^b   Langer, Robert ^d,e   Anderson, Daniel G ^d,e   De Fougerolles, Antonin ^a   Nahrendorf, Matthias ^b   Koteliansky, Victor ^a   more..

^a ALNYLAM PHARMACEUTICALS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864995694     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2011.3     Document Type: Article

References (41)

1. Bumcrot, D, Manoharan, M, Koteliansky, V and Sah, DW (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719. (Pubitemid 44764213)
2. Judge, AD, Robbins, M, Tavakoli, I, Levi, J, Hu, L, Fronda, A et al. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673.
3. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
4. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
5. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR et al. (2010). Lipidlike materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
6. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
7. Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569. (Pubitemid 351668042)
8. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364.
9. Vaishnaw, AK, Gollob, J, Gamba-Vitalo, C, Hutabarat, R, Sah, D, Meyers, R et al. (2010). A status report on RNAi therapeutics. Silence 1: 14.
10. Kumar, P, et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43. (Pubitemid 47037001)
11. Kim, SS et al. (2010). RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 18: 370-376.
12. Kim, SS et al. (2010). Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 18: 993-1001.
13. Subramanya, S et al. (2010). Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol 84: 2490-2501.
14. Peer, D et al. (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 310: 627-630. (Pubitemid 351197066)
15. Aouadi, M et al. (2009). Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458: 1180-1184.
16. Howard, KA, Paludan, SR, Behlke, MA, Besenbacher, F, Deleuran, B and Kjems, J (2009). Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 17: 162-168.
17. Nawroth, I et al. (2010). Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFa prevents radiation-induced fibrosis. Radiother Oncol 97: 143-148.
18. Robbins, M et al. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19: 991-999.
19. Nguyen, DN et al. (2009). Drug delivery-mediated control of RNA immunostimulation. Mol Ther 17: 1555-1562.
20. Geissmann, F et al. (2010). Development of monocytes, mAacrophages, and dendritic cells. Science 327: 656-661.
21. Basha, G et al. (2011). Influence of cationic lipid composition of gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 19: 2186-2200.
22. Leuschner, F et al. (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29: 1005-1010.
23. Nahrendorf, M et al. (2010). Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci USA 107: 7910-7915.
24. Landesman, Y et al. (2010). In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence 1: 16.
25. Thomas, ML (1989). The leukocyte common antigen family. Annu Rev Immunol 8: 339-369. (Pubitemid 19138017)
26. Desjardins, M and Griffiths, J (2003). Phagocytosis: latex leads the way. Curr Opin Cell Bio 15: 498-503 (Pubitemid 36928054)
27. Fratti, RA, Backer, JM, Gruenberg, J, Corvera, S and Deretic, V (2001). Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol 154: 631-644. (Pubitemid 34286167)
28. Swirski, FK, Weissleder, R and Pittet MJ. (2009). Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1424-1432.
29. Swirski, FK et al. (2009). Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616.
30. Nahrendorf, M, Pittet, MJ and Swirski, FK. (2010). Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 121: 2437-2445.
31. Ansel, KM, Harris, RB, and Cyster JG (2002). CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 16: 67-76. (Pubitemid 34143217)
32. Klein, I, Cornejo, JC, Polakos, NK, John, B, Wuensch, SA, Topham, DJ et al. (2007). Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood 110: 4077-4085. (Pubitemid 350248465)
33. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178. (Pubitemid 39545841)
34. Mori, L, Iselin, S, De Libero, G and Lesslauer, W (1996). Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157: 3178-3182. (Pubitemid 126450081)
35. de Fougerolles, AR, Sprague, AG, Nickerson-Nutter, CL, Chi-Rosso, G, Rennert, PD, Gardner, H et al. (2000). Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest 105: 721-729. (Pubitemid 30164110)
36. Nahrendorf, M et al. (2009). Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol 29: 1444-1451.
37. Novobrantseva, TI, Majeau, GR, Amatucci, A, Kogan, S, Brenner, I, Casola, S et al. (2005). Attenuated liver fibrosis in the absence of B cells. J Clin Invest 115: 3072-3082. (Pubitemid 41567572)
38. Förster, I and Rajewsky, K (1987). Expansion and functional activity of Ly-1+ B cells upon transfer of peritoneal cells into allotype-congenic, newborn mice. Eur J Immunol 17: 521-528. (Pubitemid 17094151)
39. Constien, R, Forde, A, Liliensiek, B, Gröne, HJ, Nawroth, P, Hämmerling, G et al. (2001). Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30: 36-44.
40. Terato, K, Hasty, KA, Reife, RA, Cremer, MA, Kang, AH and Stuart, JM (1992). Induction of arthritis with monoclonal antibodies to collagen. J Immunol 148: 2103-2108.
41. Terato, K, Harper, DS, Griffiths, MM, Hasty, DL, Ye, XJ, Cremer, MA et al. (1995). Collageninduced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22: 137-147. (Pubitemid 26159674)